Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression (Q28651498)

16

0 references

Domenico De Berardis

1

0 references

Andrea de Bartolomeis

Andrea De Bartolomeis

10

0 references

Marco Di Nicola

Marco Di Nicola

14

0 references

Monica Mazza

Monica Mazza

13

0 references

Michele Fornaro

Michele Fornaro

2

0 references

Giampaolo Perna

Giampaolo Perna

12

0 references

Alessandro Valchera

11

Alessandro Valchera

0 references

Carmine Tomasetti

9

Carmine Tomasetti

0 references

Felice Iasevoli

8

Felice Iasevoli

0 references

Giovanni Martinotti

15

Giovanni Martinotti

0 references

Nicola Serroni

3

Nicola Serroni

0 references

Gabriella Rapini

5

Gabriella Rapini

0 references

Daniela Campanella

4

Venkataramanujam Srinivasan

Daniela Campanella

0 references

7

Venkataramanujam Srinivasan

0 references

author name string

Luigi Olivieri

International Journal of Molecular Sciences

6

0 references

language of work or name

English

0 references

publication date

5 January 2015

3 references

13 March 2019

7 November 2019

21 September 2020

3 references

13 March 2019

7 November 2019

21 September 2020

16

0 references

page(s)

1111-30

0 references

issue

1

0 references

copyright license

Creative Commons Attribution

3 references

13 March 2019

7 November 2019

21 September 2020

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Agomelatine versus other antidepressive agents for major depression

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Is there a role for agomelatine in the treatment of anxiety disorders?A review of published data

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Role of melatonin in schizophrenia

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Seasonal affective disorder

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Agomelatine in the treatment of social anxiety disorder

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline

17 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

17 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data

6 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Agomelatine in the treatment of seasonal affective disorder

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Safety and tolerability of agomelatine: focus on hepatotoxicity

17 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Electroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug?

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Melatonin: functions and ligands

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

The mechanism, efficacy, and tolerability profile of agomelatine

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

A possible new option for migraine management: agomelatine.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Antidepressant chronotherapeutics for bipolar depression.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Sleep and circadian rhythm dysregulation in schizophrenia

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Melatonin in antinociception: its therapeutic applications.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Anhedonia and major depression: the role of agomelatine

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Role of melatonin in mood disorders and the antidepressant effects of agomelatine

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Chronic headaches and insomnia: working toward a biobehavioral model

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Synergistic mechanisms involved in the antidepressant effects of agomelatine

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Myofascial pain syndromes and their evaluation

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

A benefit-risk assessment of agomelatine in the treatment of major depression

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Anhedonia and substance dependence: clinical correlates and treatment options.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Diazepam discontinuation through agomelatine in schizophrenia with insomnia and depression.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Prophylaxis of migraine with melatonin: a randomized controlled trial.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Neurobiology of depression, fibromyalgia and neuropathic pain

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

The chronobiology and neurobiology of winter seasonal affective disorder

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Electrophysiology of the suprachiasmatic circadian clock.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Melatonin: Nature's most versatile biological signal?

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Insomnia, alcoholism and relapse

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Winter depression and the phase-shift hypothesis for bright light's therapeutic effects: history, theory, and experimental evidence

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Antidepressant action of agomelatine (S 20098) in a transgenic mouse model

3 June 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Reduced hedonic capacity in euthymic bipolar subjects: a trait-like feature?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Agomelatine treatment of major depressive disorder in Parkinson's disease: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: relationship with cyclothymic temperament and "therapeutic sensation seeking" in response towards subjective intolerance to pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Molecular rhythms in the pineal gland.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

The effects of the intraamygdalar melatonin injections on the anxiety like behavior and the spatial memory performance in male Wistar rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Melatonin modulates the GABAergic response in cultured rat hippocampal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Discrepant nocturnal melatonin levels in monozygotic twins discordant for schizophrenia and its impact on sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Augmentation of clozapine with agomelatine in partial-responder schizophrenia: a 16-week, open-label, uncontrolled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Agomelatine reversal of escitalopram-induced apathy: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Melatonin levels in premenopausal women with fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Agomelatine for the treatment of patients with fibromyalgia and depressive symptomatology: an uncontrolled, 12-week, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Agomelatine in the treatment of fibromyalgia: a 12-week, open-label, uncontrolled preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Melatonin, 3 mg, is effective for migraine prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Safety and efficacy of melatonin in pediatric migraine prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FIJMS16011111

The involvement of melatonin in the clinical status of patients with fibromyalgia syndrome

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Successful use of agomelatine in the treatment of major depression in a woman taking tamoxifen: a case report.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Agomelatine is effective in reducing insomnia in abstinent alcohol-dependent patients.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Treatment of severe sleep disorder related to alcohol-dependence with high-dose agomelatine - a case report.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Major depressive disorder, anhedonia and agomelatine: an open-label study.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Chronobiology of migraine

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: a double-blinded, placebo-controlled study.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4307293

Agomelatine adjunctive therapy for fibromyalgia

27 November 2018

1 reference

12 December 2020

Adjuvant use of melatonin for treatment of fibromyalgia

1 reference

12 December 2020

Agomelatine in the treatment of panic disorder

1 reference

12 December 2020

[Possibilities of preventive treatment of migraine with the MT1- and MT2 agonist and 5-HT2с receptor antagonist agomelatin (valdoxan)]

1 reference

12 December 2020

Circadian rhythm of mt1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse

1 reference

12 December 2020

Agomelatine for the treatment of posttraumatic stress disorder: a case report

1 reference

12 December 2020